

Anti-Apolipoprotein E APOE Monoclonal Antibody

Catalog # ABO14370

Product Information

Application	WB, IHC, IF, ICC, IP
Primary Accession	P02649
Host	Rabbit
Isotype	Rabbit IgG
Reactivity	Human, Mouse
Clonality	Monoclonal
Format	Liquid
Description	Anti-Apolipoprotein E APOE Monoclonal Antibody . Tested in WB, IHC, ICC/IF, IP applications. This antibody reacts with Human, Mouse.

Additional Information

Gene ID	348
Other Names	Apolipoprotein E, Apo-E, APOE (HGNC:613)
Calculated MW	36154
Application Details	WB 1:500-1:2000 IHC 1:50-1:200 ICC/IF 1:50-1:200 IP 1:50
Source	Eukaryota
Contents	Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol, 0.4-0.5mg/ml BSA.
Clone Names Immunogen	Clone: AbA15 A synthesized peptide derived from human Apolipoprotein E
Purification	Affinity-chromatography
Storage	Store at -20°C for one year. For short term storage and frequent use, store at 4°C for up to one month. Avoid repeated freeze-thaw cycles.

Protein Information

Name	APOE (HGNC:613)
Function	APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed: 14754908 , PubMed: 1911868 ,

PubMed:[6860692](#)). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance (PubMed:[14754908](#), PubMed:[1911868](#), PubMed:[1917954](#), PubMed:[23620513](#), PubMed:[2762297](#), PubMed:[6860692](#), PubMed:[9395455](#)). Apolipoproteins are amphipathic molecules that interact both with lipids of the lipoprotein particle core and the aqueous environment of the plasma (PubMed:[2762297](#), PubMed:[6860692](#), PubMed:[9395455](#)). As such, APOE associates with chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but shows a preferential binding to high-density lipoproteins (HDL) (PubMed:[1911868](#), PubMed:[6860692](#)). It also binds a wide range of cellular receptors including the LDL receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and LRP8 and the very low-density lipoprotein receptor/VLDLR that mediate the cellular uptake of the APOE-containing lipoprotein particles (PubMed:[12950167](#), PubMed:[1530612](#), PubMed:[1917954](#), PubMed:[20030366](#), PubMed:[20303980](#), PubMed:[2063194](#), PubMed:[2762297](#), PubMed:[7635945](#), PubMed:[7768901](#), PubMed:[8756331](#), PubMed:[8939961](#)). Finally, APOE also has a heparin-binding activity and binds heparan- sulfate proteoglycans on the surface of cells, a property that supports the capture and the receptor-mediated uptake of APOE-containing lipoproteins by cells (PubMed:[23676495](#), PubMed:[7635945](#), PubMed:[9395455](#), PubMed:[9488694](#)). A main function of APOE is to mediate lipoprotein clearance through the uptake of chylomicrons, VLDLs, and HDLs by hepatocytes (PubMed:[1911868](#), PubMed:[1917954](#), PubMed:[23676495](#), PubMed:[29516132](#), PubMed:[9395455](#)). APOE is also involved in the biosynthesis by the liver of VLDLs as well as their uptake by peripheral tissues ensuring the delivery of triglycerides and energy storage in muscle, heart and adipose tissues (PubMed:[2762297](#), PubMed:[29516132](#)). By participating in the lipoprotein-mediated distribution of lipids among tissues, APOE plays a critical role in plasma and tissues lipid homeostasis (PubMed:[1917954](#), PubMed:[2762297](#), PubMed:[29516132](#)). APOE is also involved in two steps of reverse cholesterol transport, the HDLs-mediated transport of cholesterol from peripheral tissues to the liver, and thereby plays an important role in cholesterol homeostasis (PubMed:[14754908](#), PubMed:[23620513](#), PubMed:[9395455](#)). First, it is functionally associated with ABCA1 in the biogenesis of HDLs in tissues (PubMed:[14754908](#), PubMed:[23620513](#)). Second, it is enriched in circulating HDLs and mediates their uptake by hepatocytes (PubMed:[9395455](#)). APOE also plays an important role in lipid transport in the central nervous system, regulating neuron survival and sprouting (PubMed:[25173806](#), PubMed:[8939961](#)). APOE is also involved in innate and adaptive immune responses, controlling for instance the survival of myeloid-derived suppressor cells (By similarity). Binds to the immune cell receptor LILRB4 (PubMed:[30333625](#)). APOE may also play a role in transcription regulation through a receptor-dependent and cholesterol-independent mechanism, that activates MAP3K12 and a non-canonical MAPK signal transduction pathway that results in enhanced AP-1-mediated transcription of APP (PubMed:[28111074](#)).

Cellular Location


Secreted. Secreted, extracellular space. Secreted, extracellular space, extracellular matrix. Extracellular vesicle. Endosome, multivesicular body. Note=In the plasma, APOE is associated with chylomicrons, chylomicrons remnants, VLDL, LDL and HDL lipoproteins (PubMed:[1911868](#), PubMed:[8340399](#)). Lipid poor oligomeric APOE is associated with the extracellular matrix in a calcium- and heparan-sulfate proteoglycans-dependent manner (PubMed:[9488694](#)) Lipidation induces the release from the extracellular matrix (PubMed:[9488694](#)). Colocalizes with CD63 and PMEL at exosomes and in intraluminal vesicles within multivesicular endosomes

Tissue Location

Produced by several tissues and cell types and mainly found associated with lipid particles in the plasma, the interstitial fluid and lymph

(PubMed:25173806). Mainly synthesized by liver hepatocytes (PubMed:25173806). Significant quantities are also produced in brain, mainly by astrocytes and glial cells in the cerebral cortex, but also by neurons in frontal cortex and hippocampus (PubMed:10027417, PubMed:3115992). It is also expressed by cells of the peripheral nervous system (PubMed:10027417, PubMed:25173806). Also expressed by adrenal gland, testis, ovary, skin, kidney, spleen and adipose tissue and macrophages in various tissues (PubMed:25173806)

Images



Immunohistochemical analysis of paraffin-embedded human kidney, using Apolipoprotein E Antibody.




Figure 1. Western blot analysis of Apolipoprotein E using anti-Apolipoprotein E antibody (M00015). Electrophoresis was performed on a 5-20% SDS-PAGE gel at 70V (Stacking gel) / 90V (Resolving gel) for 2-3 hours. The sample well of each lane was loaded with 30 ug of sample under reducing conditions. Lane 1: human HepG2 whole cell lysates, Lane 2: human K562 whole cell lysates. After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-Apolipoprotein E antigen affinity purified monoclonal antibody (Catalog # M00015) at 1:500 overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:500 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for Apolipoprotein E at approximately 36 kDa. The expected band size for Apolipoprotein E is at 36 kDa.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.